Strata Critical Co-CEO reports PSU vesting, tax withholding

Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported equity compensation activity in Class A common stock.

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported equity compensation activity in Class A common stock. On April 23, 2026, she acquired 630,264 shares at $0.00 per share from the vesting of performance-based restricted stock units. On April 24, 2026, 321,750 shares were disposed of at $4.92 per share, representing shares withheld by the company to cover tax obligations related to that vesting, not an open-market sale. After these transactions, she directly held 1,922,504 shares of Class A common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Tomkiel Melissa M.

Role Co-CEO and General Counsel

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A common stock, $0.0001 par value per share	321,750	$4.92	$1.58M
Grant/Award	Class A common stock, $0.0001 par value per share	630,264	$0.00	$0.00

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 1,922,504 shares (Direct)

Footnotes (2)

F1. Represents shares that were acquired upon the certification of the Compensation Committee of the Issuer's Board of Directors of the satisfaction of performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person on March 20, 2025.
F2. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of PSUs.

Key Figures

PSU-related shares acquired: 630,264 shares Acquisition price per share: $0.00/share Shares withheld for taxes: 321,750 shares +2 more

5 metrics

PSU-related shares acquired 630,264 shares Class A common stock from vested performance-based RSUs on April 23, 2026

Acquisition price per share $0.00/share Grant/award acquisition of Class A common stock

Shares withheld for taxes 321,750 shares Tax-withholding disposition on April 24, 2026 related to PSU vesting

Tax withholding price $4.92/share Value used for shares withheld to satisfy tax obligations

Shares held after transactions 1,922,504 shares Direct Class A common stock ownership following reported Form 4 activity

Key Terms

performance-based restricted stock units, PSUs, tax withholding obligations, grant/award acquisition, +1 more

5 terms

performance-based restricted stock units financial

"performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted"

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

PSUs financial

"underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

tax withholding obligations financial

"shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of PSUs"

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

What insider transactions did Strata Critical Medical (SRTA) report for Melissa M. Tomkiel?

Melissa M. Tomkiel reported a grant-related acquisition of 630,264 Class A common shares and a tax-withholding disposition of 321,750 shares. These transactions reflect equity compensation vesting and related tax withholding, rather than open-market buying or selling activity by the Co-CEO.

How many Strata Critical Medical (SRTA) shares does Melissa M. Tomkiel hold after this Form 4?

After the reported transactions, Melissa M. Tomkiel directly holds 1,922,504 shares of Strata Critical Medical Class A common stock. This total reflects the vesting of performance-based restricted stock units and the shares withheld to satisfy associated tax obligations.

What was the size of the equity award reported for Strata Critical Medical (SRTA) Co-CEO Melissa M. Tomkiel?

The filing shows an award of 630,264 Class A common shares at $0.00 per share. These shares were delivered upon certification that performance criteria for performance-based restricted stock units granted on March 20, 2025, had been satisfied by the compensation committee.

Were the Strata Critical Medical (SRTA) insider transactions open-market sales or tax withholding?

The 321,750-share disposition was for tax withholding, not an open-market sale. The company withheld these shares to satisfy tax obligations arising from the vesting of performance-based restricted stock units awarded to Melissa M. Tomkiel.

What do the performance-based restricted stock units (PSUs) mean in the SRTA Form 4 filing?

The PSUs represent equity awards that convert into shares only when performance goals are met. In this case, 630,264 shares were issued to Melissa M. Tomkiel after the compensation committee certified satisfaction of performance criteria for PSUs granted on March 20, 2025.

Does the Strata Critical Medical (SRTA) Form 4 indicate any derivative securities for Melissa M. Tomkiel?

The filing’s derivative summary is empty, indicating no derivative security transactions reported in this Form 4. The activity relates solely to non-derivative Class A common stock from vested performance-based restricted stock units and associated tax-withholding dispositions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/27/2026 - 05:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tomkiel Melissa M.

(Last)

(First)

(Middle)

C/O STRATA CRITICAL MEDICAL, INC.

666 THIRD AVENUE, 25TH FLOOR

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Co-CEO and General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A common stock, $0.0001 par value per share	04/23/2026		A		630,264⁽¹⁾	A	$0	2,244,254	D
Class A common stock, $0.0001 par value per share	04/24/2026		F		321,750⁽²⁾	D	$4.92	1,922,504	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares that were acquired upon the certification of the Compensation Committee of the Issuer's Board of Directors of the satisfaction of performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person on March 20, 2025.

2. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of PSUs.

Remarks:

	/s/ Melissa M. Tomkiel	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR